Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The DNA damage response (DDR) is a cellular network activated by DNA damage.
• Understanding DDR is vital for cancer therapy development.
• DDR pathway dysregulation is implicated in various cancers, including lymphoma.

Purpose of the Study:

• To review the role of DDR in lymphoma development.
• To explore therapeutic strategies targeting DDR in lymphoma.
• To discuss specific DDR inhibitors and their clinical potential.

Main Methods:

• Literature review of DDR mechanisms and inhibitors.
• Analysis of preclinical and clinical data for DDR inhibitors in lymphoma.
• Focus on inhibitors targeting CHK1, WEE1, ATR, DNA-PK, and PARP.

Main Results:

• Accumulating preclinical data supports DDR inhibitors as single agents or in combination.
• Specific DDR inhibitors show therapeutic potential in lymphoma models.
• Early clinical data for some inhibitors are emerging.

Conclusions:

• Targeting the DDR network offers a promising therapeutic avenue for lymphoma.
• Further clinical development of DDR inhibitors is warranted.
• Exploiting DDR vulnerabilities could improve lymphoma treatment outcomes.